Ilyang Pharmaceutical Co Ltd (007575) — Cash Flow Quality Index

Latest as of June 2025: 3.92x

Ilyang Pharmaceutical Co Ltd (007575) has a Cash Flow Quality Index of 3.92x as of June 2025. Operating cash flow of ₩2.26 Billion exceeds net income of ₩576.52 Million, indicating high earnings quality where cash backs reported profits. Explore investment intensity of Ilyang Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.

Cash Flow Quality Index

3.92x
Operating CF / Net Income

Operating Cash Flow

₩2.26 Billion
KRW

Net Income

₩576.52 Million
KRW

Data as of

Jun 2025
Most recent filing

Ilyang Pharmaceutical Co Ltd Cash Flow Quality Index (2015–2024)

Historical Cash Flow Quality Index for Ilyang Pharmaceutical Co Ltd across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 007575 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Ilyang Pharmaceutical Co Ltd (2015–2024)

Year-by-year earnings quality comparison for Ilyang Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see Ilyang Pharmaceutical Co Ltd market capitalisation.

Year Quality Index Operating CF (KRW) Net Income YoY Change
2024 0.55x ₩5.61 Billion ₩10.26 Billion ▼ -64.8%
2022 1.56x ₩29.94 Billion ₩19.24 Billion ▼ -66.6%
2021 4.66x ₩67.02 Billion ₩14.38 Billion ▼ -11.8%
2020 5.28x ₩57.48 Billion ₩10.88 Billion ▲ +45.8%
2019 3.62x ₩36.19 Billion ₩9.98 Billion ▼ -24.4%
2017 4.79x ₩30.03 Billion ₩6.26 Billion ▲ +4.9%
2016 4.57x ₩26.98 Billion ₩5.91 Billion ▼ -50.0%
2015 9.13x ₩40.27 Billion ₩4.41 Billion
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.